Table 2.
Results of the surface under the cumulative ranking curve (SUCRA)
| Treatments | SUCRA values | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HbA1c | 2-h PPG | FPG | Body weight | All-cause mortality | MACE | Hypoglycemia | SAE | UTI | Diarrhea | |
| Placebo | 0.1 | 0.7 | 2.1 | 39.1 | 32.5 | 27.9 | 46.9 | 42 | 68 | 26 |
| SGLT-2 Inhibitor | 77.5 | 95.1 | 97.3 | 100 | 60.1 | 81.5 | 74.1 | 77.6 | 31.5 | 49.2 |
| DPP-4 inhibitor | 45.8 | 45.8 | 39.7 | 48.9 | 60.6 | 82.7 | 77.7 | 48.7 | 47.9 | 73.5 |
| Sulfonylurea | 63.3 | 42 | 62.9 | 16.4 | 40.3 | 42.6 | 6.4 | 50.7 | 52.6 | 62.5 |
| Thiazolidinedione | 76.2 | 59 | 78.7 | 0.3 | 75.1 | 15.2 | 72.1 | 9.7 | 75.3 | 83.9 |
| AGI | 79.3 | 67.4 | 56.7 | 76.4 | 51.4 | NAj | 60.6 | 84.8 | 24.9 | 34 |
| Met | 22.4 | 40.1 | 13.5 | 68.9 | 31.4 | NA | 53.9 | 36.4 | NA | 20.9 |
| Meglitinide | 36.4 | NA | 49.2 | NA | 48.6 | NA | 8.4 | NA | NA | NA |
Boldface is used to indicate the highest and lowest SUCRA values for each parameter
SUCRA surface under the cumulative ranking curve, AGI alpha-glucosidase inhibitor, HbA1c glycated hemoglobin, Met high-dose metformin, 2-h PPG 2-h postprandial glucose, FPG fasting plasma glucose, MACE major adverse cardiovascular event, SAE serious adverse event, UTI urinary tract infection, NA not applicable